AbbVie nabs FDA's orphan drug tag for Humira in HS

AbbVie ($ABBV) is working to lessen its reliance on blockbuster Humira, which is already facing biosimilar competition in India. But it's also working to broaden the drug's label, and on that front, it got a boost from the FDA on Friday. The arthritis and psoriasis drug grabbed the agency's orphan drug designation for its cash cow for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.